BLLN trades 8.0% below Wall Street's consensus target of $127.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BLLN achieves its forward estimates and maintains a stable P/E multiple of 120.3x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, BillionToOne, Inc. (BLLN) has a Wall Street consensus price target of $127.50, based on estimates from 4 covering analysts. With the stock currently trading at $118.04, this represents a potential upside of +8.0%. The company has a market capitalization of $5.43B.
Analyst price targets range from a low of $125.00 to a high of $130.00, representing a 4% spread in expectations. The median target of $127.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BLLN trades at a trailing P/E of 1853.1x and forward P/E of 120.3x. Analysts expect EPS to grow +106.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NTRANatera, Inc. | $40.3B | $281.27 | $261.00 | -7.2% | Buy | — | 27 |
ILMNIllumina, Inc. | $29.1B | $191.76 | $156.27 | -18.5% | Buy | 36.6x | 50 |
PGNYProgyny, Inc. | $2.4B | $30.78 | $30.33 | -1.5% | Buy | 23.7x | 20 |
CDNACareDx, Inc | $1.5B | $28.31 | $27.00 | -4.6% | Buy | 30.3x | 13 |
EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
PACBPacific Biosciences of California, Inc. | $485M | $1.56 | $1.00 | -35.9% | Buy | — | 18 |
PRMEPrime Medicine, Inc. | $721M | $3.99 | $7.00 | +75.4% | Buy | — | 9 |
TMOThermo Fisher Scientific Inc. | $192.0B | $516.62 | $592.45 | +14.7% | Buy | 20.8x | 42 |
DHRDanaher Corporation | $137.4B | $194.19 | $230.89 | +18.9% | Buy | 23.0x | 43 |
AAgilent Technologies, Inc. | $37.0B | $131.14 | $154.75 | +18.0% | Buy | 21.7x | 41 |
Quick answers to the most common questions about buying BLLN stock.
The consensus price target for BLLN is $127.5, close to the current price of $118.04 (8.0% implied move). Based on 4 analyst estimates, the stock appears fairly valued near current levels.
BLLN has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $127.5 implies 8.0% upside from current levels.
At a forward P/E of 120.2649x, BLLN trades at a premium valuation. The consensus price target of $127.5 (8.0% upside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $130 for BLLN, while the most conservative target is $125. The consensus of $127.5 represents the median expectation. These targets typically reflect 12-month expectations.
BLLN is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BLLN stock forecast based on 4 Wall Street analysts shows a consensus price target of $127.5, with estimates ranging from $125 (bear case) to $130 (bull case). The median consensus rating is "Buy".
BLLN trades at a forward P/E ratio of 120.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 1853.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
BLLN appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $127.5 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BLLN analyst price targets range from $125 to $130, a 4% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $127.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.